Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant

Journal of Nuclear Medicine

Volumn 39, Issue 3, 1998, Pages 440-448

  Spence, Alexander M ^a,b   Muzi, Mark ^a   Graham, Michael M ^a   O'Sullivan, Finbarr ^a   Krohn, Kenneth A ^a   Link, Jeanne M ^a   Lewellen, Thomas K ^a   Lewellen, Barbara ^a   Freeman, Scott D ^a   Berger, Mitchel S ^a   Ojemann, George A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brain neoplasm; Glioma; Glucose metabolism; Lumped constant; PET

Indexed keywords

FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; HEXOKINASE;

ARTICLE; AUTORADIOGRAPHY; BRAIN TISSUE; CALCULATION; CLINICAL ARTICLE; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; GLUCOSE METABOLISM; HUMAN; HYPOTHESIS; METABOLIC RATE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; GLUCOSE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SUPRATENTORIAL NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031930393     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer 1988;62:1074-1078.
2. Coleman RE, Huffman JM, Hanson MW, Sostman HD, Schold SCJ. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991;32:616-622.
3. 18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-371.
4. 18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 1991;29:347-355.
5. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993;79:853-858.
6. Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S. Glucose consumption in recurrent gliomas. Neurosurgery 1993;33:28-33.
7. Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent rumors from post-treatment changes with F-18 FDG PET. Radiographics 1992;12:269-279.
8. Tyler JL, Diksic M, Villemure JG, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987;28:1123-1133.
9. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. J Neurosurg 1988;69:830-838.
10. 82Rb positron emission tomography. J Comput Assist Tomogr 1987;11:563-570.
11. Schifter T, Hoffman JM, Hanson MW, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 1993;17: 509-516.
12. McKusick KA, Fischman AJ, Hochberg FH, Alpert NM, Corriera JA, Strauss HW. TL-201 and F-18 deoxyglucose in detection of recurrent primary brain tumor [Abstract]. J Nucl Med 1991;32:955.
13. Schifter T, Huffman JM, Hanson MW, et al. Serial FDG-PET studies in the management of primary CNS tumors [Abstract]. J Nucl Med 1991;32:932.
14. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
15. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-1329.
16. Mineura K, Yasuda T, Kowada M, Ogawa T, Shishido F, Uemura K. Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. J Neurooncol 1987;5:277-285.
17. Ogawa T, Uemura K, Shishido F, et al. Changes of cerebral blood flow and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 1988;12:290-297.
18. 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991;32:197-202.
19. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-822.
20. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388.
21. Rozental JM, Levine RL, Nickles RJ. Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance. J Neurooncol 1991;10:75-83.
22. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 1992;12:159-165.
23. Herholz K, Ziffling P, Staffen W, et al. Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET. Eur J Cancer Clin Oncol 1988;24:1139-1150.
24. Sokoloff L. The deoxyglucose method: theory and practice. Eur Neurol 1981;20:137-145.
25. 11C]deoxyglucose. J Cereb Blood Flow Metab 1985;5:179-192.
26. Kapoor R, Spence AM, Muzi M, Graham MM, Abbott GL, Krohn KA. Determination of the deoxyglucose and glucose phosphorylation ratio and the lumped constant in rat brain and a transplantable rat glioma. J Neurochem 1989;53:37-44.
27. Spence AM, Graham MM, Muzi M, et al. Deoxyglucose lumped constant estimated in a transplanted rat astrocytic glioma by the hexose utilization index. J Cereb Blood Flow Metab 1990;10:190-198.
28. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
29. Shiue C-Y, Wolf AP. The synthesis of 1-[C-11]-D-glucose for measurement of brain glucose metabolism [Abstract]. J Nucl Med 1981;22:P58.
30. Shiue C-Y, Wolf AP. 1-11-C-D-glucose and related compounds, US Patent 4439414A, 1984.
31. 11C]D-glucose. Appl Radiat Isot 1993;44:971-980.
32. Lewellen TK, Bice AN, Harrison RL, Pencke MD, Link JM. Performance measurements of the SP-3000/UW time-of-flight emission tomograph. IEEE Trans Nucl Sci 1988;35:665-667.
33. Lewellen TK, Bice AN, Miyaoka RS, Harrison RL. Performance improvements for the SP-3000 time-of-flight positron emission tomograph [Abstract]. J Nucl Med 1990;31: 863.
34. Lewellen TK, Harrison RL, Bice AN. An experimental evaluation of the effect of time-of-flight information in image reconstructions for the Scanditronix/PETT electronics SP-3000 positron emission tomograph-preliminary results. IEEE Trans Nucl Sci 1989;36:1095-1099.
35. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994;35:1398-1406.
36. Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS, Stearns CW, Schubert SF. Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 1996;43:2199-2206.
37. Lewellen TK, Kohlmyer SG, Miyaoka RS, Schubert S, Stearns CW. Investigation of the count rate performance of General Electric Advance positron emission tomograph. IEEE Trans Nucl Sci 1995;42:1051-1057,
38. Graham MM, Lewellen BL. High-speed automated discrete blood sampling for positron emission tomography. J Nucl Med 1993;34:1357-1360.
39. Blomqvist G, Stone-Elander S, Halldin C, et al. Positron emission tomographic measurements of cerebral glucose utilization using [1-11-C]D-glucose. J Cereb Blood Flow Metab 1990;10:467-483.
40. Gjedde A, Diemer NH. Autoradiographic determination of regional brain glucose content. J Cereb Blood Flow Metab 1983;3:303-310.
41. Dennis JE, Gay DM, Welsch RE. An adaptive non-linear least squares algorithm. ACM Trans Math Software 1981;7:348-383.
42. Crane PD, Pardridge WM, Braun LD, Nyerges AM, Oldendorf WH. The interaction of transport and metabolism on brain glucose utilization: a reevaluation of the lumped constant. J Neurochem 1981;36:1601-1604.
43. Braun LD, Miller LP, Pardridge WM, Oldendorf WH. Kinetics of regional blood-brain barrier glucose transport and cerebral blood flow determined with the carotid injection technique in conscious rats. J Neurochem 1985;44:911-915.
44. Choi Y, Hawkins RA, Huang S-C, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med 1994;35: 818-823.
45. 18F]fluorodeoxyglucose kinetic model in calculations of myocardial glucose metabolism during ischemia. J Nucl Med 1983;24:1060-1064.
46. 18F]fluoro-2-deoxyglucose in tumor-bearing rats: Chromatographic and enzymatic studies. Int J Radiat Appl Instrum B 1986;13:577-581.
47. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995;36:297-306.
48. Herholz K, Wienhard K, Heiss WD. Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 1990;2:240-265.
49. Bass L, Bodsch W, Robinson PJ, Young MO. Metabolites of 2-deoxyglucose in rat brain at 12-24 h: bounds on kinetic constants. Am J Physiol 1987;253:E453-E460.
50. 18F]fluoro-2-deoxy-D-glucose (FDG) in mammary tumors of antiestrogen-treated rats. Nucl Med Biol 1995;22:483-489.
51. 19F nuclear magnetic resonance spectroscopy. J Neurochem 1986;46:198-201.
52. O'Connell TM, London RE. Identification of 2-fluoro-2-deoxy-D-glucose metabolites by 19F(1H) hetero-RELAY. J Magn Resonance B 1995;109:264-269.
53. Spence AM, Graham MM, Muzi M, et al. Feasibility of imaging pentose cycle glucose metabolism in gliomas with PET: studies in rat brain tumor models. J Nucl Med 1997;38:617-624.
54. Hawkins RA, Mans AM. Intermediary metabolism of carbohydrates and other fuels. In: Lajtha, A. eds. Handbook of neurochemistry, vol. 2. New York: Plenum Press; 1983:259-294.
55. Bassingthwaighte JB, Chan IS, Wang CY. Computationally efficient algorithms for convection-permeation-diffusion models for blood-tissue exchange. Ann Biomed Eng 1992;20:687-725.
56. Lear JL, Kasliwal RK. Autoradiographic measurement of cerebral lactate transport rate constants in normal and activated conditions. J Cereb Blood Flow Metab 1991;11: 576-580.
57. Florida A, Paggi MG, Fanciulli M. Modulation of glycolysis in neuroepithelial tumors. J Neurosurg Sci 1989;33:55-64.
58. Oudard S, Poirson F, Miccoli L, et al. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 1995;62:216-222.
59. Bennett MJ, Timperley WR, Taylor CB, Hill AS. Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur J Cancer 1978;14:189-193.
60. Katzen HM. The multiple forms of mammalian hexokinase and their significance to the action of insulin. Adv Enzyme Regul 1967;5:335-356.
61. Kurokawa M, Oda S, Tsubotani E, Fujiwara H, Yokoyama K, Ishibashi S. Characterization of hexokinase isoenzyme types I and II in ascites tumor cells by an interaction with mitochondrial membrane. Mol Cell Biochem 1982;45:151-157.
62. Sprengers ED, Koenderman AH, Staal GE. Mitochondrial and cytosolic hexokinase from rat brain: one and the same enzyme? Biochim Biophys Acta 1983;755:112-118.
63. Wilson JE. Brain hexokinase, the prototype ambiquitous enzyme. Curr Top Cell Regul 1980;16:1-54.
64. Eigenbrodt E, Fister P, Reinacher M. New perspectives on carbohydrate metabolism in tumor cells. In: Beitner, R. ed. Regulation of carbohydrate metabolism. Boca Raton: CRC Press; 1985:141-179.
65. Kraaijenhagen RJ, Rijksen G, Staal GE. Hexokinase isozyme distribution and regulatory properties in lymphoid cells. Biochim Biophys Actra 1980;631:402-411.
66. Oude Weernink PA, Rijksen G, Staal GE. Phosphorylation of pyruvate kinase and glycolytic metabolism in three human glioma cell lines. Tumour Biol 1991;12:339-352.
67. Singh M, Singh VN, August JT, Horecker BL. Transport and phosphorylation of hexoses in normal and Rous sarcoma virus-transformed chick embryo fibroblasts. J Cell Physiol 1978;97:285-292.
68. Cayanis E, Balinsky D. Comparative kinetic properties of human hexokinases. Int J Biochem 1975;6:741-749.
69. Grossbard L, Schimke RT. Multiple hexokinases of rat tissues. Purification and comparison of soluble forms. J Biol Chem 1966;241:3546-3560.
70. Katzen HM, Schimke RT. Multiple forms of hexokinase in the rat: tissue distribution, age dependency, and properties. Proc Natl Acad Sci USA 1965;54:1218-1225.
71. Ureta T. The comparative isozymology of vertebrate hexokinases. Comp Biochem Physiol B 1982;71:549-555.
72. Lusk JA, Manthorpe CM, Kao-Jen J, Wilson JE. Predominance of the cytoplasmic form of brain hexokinase in cultured astrocytes. J Neurochem 1980;34:1412-1420.
73. 18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation 1995;91:2435-2444.
74. 18F]2-fluoro-2-deoxy-D-mannose in patients with focal brain lesions. J Cereb Blood Flow Metab 1991;11:485-491.
75. 18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods. J Cereb Blood Flow Metab 1987;7:161-172.
76. American Academy of Neurology, Therapeutics, and Technology Assessment Subcommittee Assessment. Positron emission tomography. Neurology 1991;41:163-167.
77. Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991;15:796-801.
78. Theodore WH. Antiepileptic drugs and cerebral glucose metabolism. Epilepsia 1988;29(suppl 2):S48-S55.
79. Fiorelli M, Blin J, Bakchine S, Laplane D, Baron JC. PET studies of cortical diaschisis in patients with motor hemi-neglect. J Neurol Sci 1991;104:135-142.
80. Kushner M, Alavi A, Reivich M, Dann R, Burke A, Robinson G. Contralateral cerebellar hypometabolism following cerebral insult: a positron emission tomographic study. Ann Neurol 1984;15:425-434.
81. Kushner M, Tobin M, Alavi A, et al. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. J Nucl Med 1987;28:1667-1670.
82. Rozental JM, Levine RL, Nickles RJ, Dobkin JA, Hanson JM. Cerebral diaschisis in patients with malignant glioma. J Neurooncol 1990;8:153-161.
83. Di Chiro G, Brooks RA. PET quantitation: blessing and curse. J Nucl Med 1988;29:1603-1604.